Gangwal Healthcare is a contract manufacturer based in India. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Customs aggregates show $2.0M of exports covering 199 molecules to 33 destinations in 2025.
| Molecule | Regulators | Docs |
|---|---|---|
| Isoxsuprine | US FDA | 1 |
| Salmeterol | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 1 | None |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $239K | 10 |
| 2025 | Not reported | $2.0M | 33 |
| 2024 | Not reported | $652K | 26 |
| 2023 | Not reported | $562K | 20 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Gangwal Healthcare comes back tiered against every other supplier able to file there.
Start for free